Compare Fidelity National Information Servcs Inc (FIS) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Fidelity National Information Servcs Inc vs Novartis AG — how do they compare? Fidelity National Information Servcs Inc trades at $34.36 (market cap $17.44B), while Novartis AG trades at $142.04 (market cap $274.00B). The key difference: Novartis AG is far larger — about 15.7× Fidelity National Information Servcs Inc's market cap, and Fidelity National Information Servcs Inc pays the higher dividend (5.2%). Which is the better fit depends on your goals — on Pluang, investors hold Fidelity National Information Servcs Inc for 88 Days and Novartis AG for 82 Days on average.
| FIS | NVS | |
|---|---|---|
Market Cap | $17.44B | $274.00B |
Volume | 6,437,765 | 1,852,137 |
Sector | Technology | Health |
52-Week High | $68.57 | $168.62 |
52-Week Low | $32.44 | $121.80 |
Typical Hold Time | 88 Days | 82 Days |
Enterprise Value | $37.95B | $315.32B |
Dividend Yield | 5.2% | 3.31% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FIS trades at $34.34, up 2.75% today, with a bearish technical signal despite recent earnings beats in Q1 and Q2 2026. The company shows improving fundamentals with revenue growth from $10.7B in 2025 to projected $12.2B in 2026 and strong profitability metrics including 27.65% net income margin. Recent news highlights strategic wins in core banking modernization and embedded finance platforms.
The stock presents a compelling value opportunity with a low P/E of 5.2 and analyst consensus target of $47.54 (38% upside), though risks include significant debt load and volatile cash flow trends. Institutional sentiment remains positive with 57% buy ratings, but technical weakness near key support at $33 requires monitoring.
Novartis (NVS) trades at $143.11, up 1.65% with mixed technical signals showing neutral momentum. The company maintains strong profitability with 22.5% net margins and recently announced a $7.8B licensing deal with China's Abogen. Recent earnings show two beats and one miss in the last three quarters, with Q3 2026 results pending. The stock trades below the consensus price target of $146, suggesting modest upside potential from current levels.
Novartis presents a balanced investment case with strong cash flow generation and profitability offset by recent clinical setbacks and M&A scrutiny. The $7.8B Abogen partnership expands the autoimmune pipeline, but investors face risks from patent cliffs and drug development failures. Analyst consensus leans cautious with 68% hold ratings, reflecting uncertainty around pipeline execution amid ongoing strategic repositioning.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Fidelity National Information Servcs Inc
Fidelity National Information Services' legacy operations provide core and payment processing services to banks, but its business has expanded over time. By acquiring Sungard in 2015, the company now provides record-keeping and other services to investment firms. With the acquisition of Worldpay in 2019, FIS now provides payment processing services for merchants and holds leading positions in the United States and United Kingdom. About a fourth of revenue is generated outside North America.
Read more on FIS →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
